The ratings of major US investment banks are used to track the latest valuations and target prices on Wall Street daily, and to explore potential equity investment opportunities.

Risk warning:

Investing in small-cap stocks can be risky. Be prepared for potential challenges related to liquidity, high volatility, limited information, and financial instability. Always diversify your investments.

Today's key assessments and concerns

Piper Sandler: Maintaining an "overweight" rating on MeiraGTx Hldgs ( MEIRAGTX HOLDINGS PLC(MGTX.US) ), while raising the price target from $28 to $30.

RBC Capital: Maintaining its "Outperform Market" rating for 4D Molecular Therapeutics ( 4D Molecular Therapeutics, Inc.(FDMT.US) ), while raising its price target from $26 to $32.

Wedbush: Maintaining WAVE Life Sciences ( Wave Life Sciences Ltd.(WVE.US) ) rating at "Outperform Market", while raising the price target from $18 to $20.

Litchfield Hills: Initial rating for FG Nexus ( FG Nexus(FGNX.US) ) stock at "Buy", with a target price of $12.

Piper Sandler: Maintaining Arcturus Therapeutics' rating ( Arcturus Therapeutics(ARCT.US) ) at "Overweight", while lowering the target price from $140 to $72.

The symbol	Classification	Target price	Current price	Percentage of potential increase/decrease	(Classification) Agency
MEIRAGTX HOLDINGS PLC(MGTX.US)	to lift	$30.0	$8.9	237.08%	Piper Sandler
4D Molecular Therapeutics, Inc.(FDMT.US)	to lift	$32.0	$10.8	196.3%	RBC Capital
Wave Life Sciences Ltd.(WVE.US)	to lift	$20.0	$7.26	175.48%	Wedbush
CytomX Therapeutics, Inc.(CTMX.US)	to lift	$10.0	$4.1	143.9%	HC Wainwright & Co.
4D Molecular Therapeutics, Inc.(FDMT.US)	to lift	$26.0	$10.8	140.74%	Chardan Capital
FG Nexus(FGNX.US)	Initial classification	$12.0	$3.02	297.35%	Litchfield Hills
Arcturus Therapeutics(ARCT.US)	cut	$72.0	$8.67	730.45%	Piper Sandler
Nkarta(NKTX.US)	cut	$11.0	$2.01	447.26%	Stifel
4D Molecular Therapeutics, Inc.(FDMT.US)	cut	$33.0	$10.8	205.56%	Barclays
Sable Offshore(SOC.US)	cut	$20.0	$7.23	176.63%	Jefferies

comments:
Target price unit and current price: US Dollar;
Current price: As of the latest closing price of US stocks;
Potential percentage increase/potential decrease = (Agency target price - current price) / current price 100% (Current price = Last closing price up to the time of the count)

Lifting

JP Morgan: Maintaining Circle Internet Group's ( Circle(CRCL.US) ) rating at "Underweight", while raising the price target from $93 to $94.

Morgan Stanley: Maintaining CoreWeave's rating ( CoreWeave(CRWV.US) ) at "Market-in-Similar Weight", while raising the price target from $91 to $99.

Argus Research: Upgrades Estée Lauder ( Estee Lauder Companies Inc. Class A(EL.US) stock to "buy", with a target price of $105.

Barclays: Maintaining an "overweight" rating on Grab Holdings ( Grab(GRAB.US) ), while raising its price target from $6.5 to $7.

Tigress Financial: Maintaining a "buy" rating on T-Mobile US T-Mobile(TMUS.US) ) stock, while raising the price target from $305 to $310.

Keefe, Bruyette & Woods: Maintaining a "Market Match" rating on Ares Commercial Real Estate Corporation(ACRE.US) , raising the price target from $4.50 to $4.75.

Morgan Stanley: Maintaining Adaptive Biotechnologies(ADPT.US) ' rating at "Market Weight", while raising the price target from $11 to $16.

Citigroup: Maintaining a "neutral" rating on American Eagle Outfitters ( American Eagle Outfitters, Inc.(AEO.US) ), while raising the price target from $15 to $18.

Morgan Stanley: Maintaining AerCap Holdings' rating ( AerCap Holdings NV(AER.US) ) at "Market Weight", while raising the price target from $120 to $150.

Susquehanna: Maintaining a "positive" rating on AerCap Holdings ( AerCap Holdings NV(AER.US) ), while raising the price target from $134 to $157

Citigroup: Maintaining a "neutral" rating on Akamai Technologies Akamai(AKAM.US) ) stock, while raising its price target from $85 to $88.

First Coverage

Truist Securities: Initial rating for Alkermes ( Alkermes Plc(ALKS.US) ) stock at "Buy", with a target price of $50.

Litchfield Hills: Initial rating for FG Nexus ( FG Nexus(FGNX.US) ) stock at "Buy", with a target price of $12.

UBS: Keysight Technologies ( Keysight Technologies Inc(KEYS.US) ) has a preliminary rating of "buy" on its stock, with a target price of $220.

Piper Sandler: Initial rating for Li Auto LI Auto(LI.US) stock at "neutral", with a target price of $19.

CICC: Initial rating for Nebius Group ( Nebius Group(NBIS.US) ) at "outperforms the market", with a price target of $143.

Citigroup: Initial rating for Sunoco Corp ( SunocoCorp LLC(SUNC.US) ) at "Buy", with a target price of $65.

Needham: A preliminary rating of "buy" for Waystar Holding ( Waystar Holding Corp.(WAY.US) ) stock, with a target price of $46.

reduction

Baird: Maintaining a "neutral" rating on CRISPR Therapeutics ( CRISPR Therapeutics AG(CRSP.US) ), while lowering its price target from $52 to $44.

Evercore ISI Group: Maintaining CoreWeave's ( CoreWeave(CRWV.US) ) rating at "Outperform Market", while lowering the price target from $175 to $160.

Macquarie: Maintaining a "neutral" rating on CoreWeave ( CoreWeave(CRWV.US) ), while lowering the price target from $140 to $115

Mizuho: Maintaining a "neutral" rating on CoreWeave ( CoreWeave(CRWV.US) ), while lowering the price target from $150 to $120.

B of A Securities: Maintaining a "neutral" rating on CoreWeave ( CoreWeave(CRWV.US) ), while lowering the price target from $168 to $140.

JP Morgan: Lowered its rating on CoreWeave ( CoreWeave(CRWV.US) ) stock to "neutral," with a price target of $110.

Jefferies: Maintaining a "buy" rating on CoreWeave ( CoreWeave(CRWV.US) ), while lowering the price target from $180 to $155.

Goldman Sachs: Maintaining a "sell" rating on Marriott Vacations Worldwide ( Marriott Vacations Worldwide Corporation(VAC.US) ), while lowering its price target from $63 to $54.

Mizuho: Lowered its rating on Marriott Vacations Worldwide ( Marriott Vacations Worldwide Corporation(VAC.US) ) to "neutral," with a price target cut from $85 to $58.

Keefe, Bruyette & Woods: Maintaining Voya Financial's ( Voya Financial, Inc.(VOYA.US) ) rating at "Outperform Market", while lowering the price target from $86 to $84.

Wells Fargo: Maintaining an "overweight" rating on WAVE Life Sciences ( Wave Life Sciences Ltd.(WVE.US) ), while lowering the price target from $18 to $16.

Editor's Note: This content was created by Saham's AI-powered SaaS tool and reviewed by our editorial team.
Risk Warning: Investing involves risk. Securities may rise, fall, or become worthless. Investing does not guarantee profits and may result in losses. Past performance is not necessarily indicative of future results. Before making any investment decision, investors should assess their financial situation, investment objectives, experience, risk tolerance, and understand the nature of the investment products and their associated risks. For more details on the nature and risks of each investment product, please read the relevant offering documents carefully. If you have any questions, it is advisable to seek independent professional advice.